SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001193125-22-127861
Filing Date
2022-04-28
Accepted
2022-04-28 16:58:31
Documents
2
Group Members
NAN FUNG GROUP HOLDINGS LTDNAN FUNG LIFE SCIENCES HOLDINGS LTDNF INVESTMENT HOLDINGS LTDPIVOTAL BIOVENTURE PARTNERS FUND I G.P., L.P.PIVOTAL BIOVENTURE PARTNERS FUND I U.G.P., LTD.PIVOTAL LIFE SCIENCES HOLDINGS LTDPIVOTAL PARTNERS LTD.

Document Format Files

Seq Description Document Type Size
1 SC 13D d335016dsc13d.htm SC 13D 152249
2 EXHIBIT 1 d335016dex991.htm EX-99.1 11904
  Complete submission text file 0001193125-22-127861.txt   166219
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Subject) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-91586 | Film No.: 22867732
SIC: 2834 Pharmaceutical Preparations

Mailing Address 501 SECOND STREET, SUITE 200 SAN FRANCISCO CA 94107
Business Address 501 SECOND STREET, SUITE 200 SAN FRANCISCO CA 94107 (345) 949 1040
Pivotal bioVenture Partners Fund I, L.P. (Filed by) CIK: 0001695076 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 0331
Type: SC 13D